Rationale for combination therapy of chronic myelogenous leukemia with imatinib and irradiation or alkylating agents: Implications for pretransplant conditioning

被引：0
|
作者：
Fruehauf, S [1 ]
Topaly, J [1 ]
Schad, M [1 ]
Ho, A [1 ]
Zeller, W [1 ]
机构：
[1] Univ Heidelberg, D-6900 Heidelberg, Germany
来源：
EXPERIMENTAL HEMATOLOGY | 2002年 / 30卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
224
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [41] Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance
    Marcucci, G
    Perrotti, D
    Caligiuri, MA
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1248 - 1252
  • [42] COMBINATION THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALFA AND OTHER CYTOKINES
    KLOKE, O
    SEMINARS IN HEMATOLOGY, 1993, 30 (03) : 22 - 23
  • [43] Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase.
    Yang, Dongguang
    Zhang, Ri
    Shen, Yunfeng
    Zhang, Xuhui
    Wu, De Pei
    BLOOD, 2006, 108 (11) : 612A - 612A
  • [44] Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate
    Zhang, Bin
    Strauss, Adam C.
    Chu, Su
    Li, Min
    Ho, Yinwei
    Shiang, Keh-Dong
    Snyder, David S.
    Huettner, Claudia S.
    Shultz, Leonard
    Holyoake, Tessa
    Bhatia, Ravi
    CANCER CELL, 2010, 17 (05) : 427 - 442
  • [45] Tipifarnib (ZARNESTRA™) and imatinib (GLEEVEC™) combination therapy in patients with advanced chronic myelogenous leukemia (CML):: Preliminary results of a phase I study.
    Gotlib, J
    Mauro, M
    O'Dwyer, ME
    Fechter, L
    Dugan, K
    Kuyl, J
    Yekrang, A
    Mori, M
    Rackoff, W
    Coutre, S
    Druker, B
    Greenberg, PL
    BLOOD, 2003, 102 (11) : 909A - 910A
  • [46] Prognostic Factors Associated with Complete Cytogenetic Response in Patients with Chronic Myelogenous Leukemia on Imatinib Mesylate Therapy
    Cojbasic, Irena
    Macukanovic-Golubovic, Lana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2010, 138 (5-6) : 305 - 308
  • [47] Significance of myelosuppression (MS) during the course of therapy with imatinib in patients with chronic myelogenous leukemia (CML) in chronic phase.
    Sneed, TB
    Kantarjian, HM
    Talpaz, M
    O'Brien, S
    Rios, MB
    Wierda, W
    Thomas, D
    Cortes, JE
    BLOOD, 2002, 100 (11) : 787A - 787A
  • [48] Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia - Remarkable activity with room for improvement
    Tefferi, Ayalew
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (03) : 175 - 177
  • [49] Imatinib in combination with 17-allylamino-17-demethoxy-geldanamycin (17-AAG) for treatment of chronic myelogenous leukemia
    Topaly, J
    Schad, M
    Zeller, W
    Fruehauf, S
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (06) : 72 - 72
  • [50] European sub-registry of chronic myelogenous leukemia (CML) patients (pts) in failure after imatinib therapy (IFP): Rationale, study design and current enrollment.
    Guilhot, Joelle
    Tartarin, Florence
    Pfirmann, Markus
    Nagler, Arnon
    Nicolini, Franck
    Rousselot, Philippe
    Porkka, Kimmo
    Ossenkoppele, Gert
    Stentoft, Jesper
    Cervantes, Francisco
    Rosti, Gianantonio
    Thaler, Josef
    le Coutre, Philipp
    Hasford, Joerg
    Hehlmann, Rudiger
    Guilhot, Francois
    BLOOD, 2006, 108 (11) : 274B - 274B
12345